Earnings per share for the last twelve months: Cytori Therapeutics (PSTV)

PSTV (Cytori Therapeutics) - company brandmark

Risks of radiopharmaceutical platform failure and R&D expenses create tension, yet a strong scientific team and government support bolster market confidence. The TTM annual earnings per share help resolve this dispute, and -3.29 sets the current value of the metric. Management's pragmatic approach to capital allocation and patent protection ensures the resilience of Plus Therapeutics, Inc. (PSTV) in the fight against cancer.

PSTV (Cytori Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 08/03/2026

Analytical breakdowns for Plus Therapeutics, Inc. (PSTV)

- stock price and consensus target price:
Stock Price Plus Therapeutics, Inc.|PSTV - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Plus Therapeutics|PSTV - Business Value
- shareholders' equity book value data:
Book Value per Share Plus Therapeutics|PSTV - Company Net Assets|Market Capitalization to Book Value Ratio plustherapeutics.com|PSTV - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Plus Therapeutics, Inc.|PSTV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Plus Therapeutics, Inc.|PSTV - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Cytori Therapeutics|PSTV - Company Long-Term Debt|Company Current Liabilities Plus Therapeutics|Quick Liquidity plustherapeutics.com
- net income and valuation multiples indicators:
PSTV - Net Financial Result|Future Profit Plus Therapeutics, Inc.|PSTV - Company Value to Net Income|Projected Price to Earnings Cytori Therapeutics|PSTV - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple PSTV|PSTV - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Plus Therapeutics|PSTV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months plustherapeutics.com|PSTV - Earnings per share increase in current year|Earnings growth forecast for next year Plus Therapeutics, Inc.
- revenue and sales details:
PSTV - Revenue and Sales Volume|Company Projected Revenue Plus Therapeutics, Inc.|PSTV - Price-to-Sales Ratio|Forward P/S Multiple Plus Therapeutics, Inc.
Summary company analysis:PSTV - Plus Therapeutics Inc
Mass-produced product of Cytori Therapeutics

The market values Plus Therapeutics, Inc. (PSTV) through the lens of its innovative radiotherapy methods' effectiveness. This indicator measures annual net income per share, filtering out market noise and capitalization volatility. By analyzing the rolling earnings per share trend, an investor can discern the actual return on their business stake. For Plus Therapeutics, Inc. (PSTV), this reflects the conversion of regular isotope sales into the final financial result. Growth in this metric confirms the sustainability of the business model.

Competitor analysis for Plus Therapeutics, Inc.

olema.com - Net earnings per share (EPS TTM)|PBYI - Net earnings per share (EPS TTM)|Greenwich LifeSciences (GLSI) - Earnings per share for the last twelve months|Earnings per share for the last 12 months ZNTL|MGNX (macrogenics.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Processa Pharmaceuticals (PCSA)|Net earnings per share (EPS TTM) EGRX